News | July 22, 2025
AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Subscribe To Our Newsletter & Stay Updated
